DMAC News and Press, DiaMedica Therapeutics Inc. From 05/17/21

Initiating ReMEDy2 – Pivotal Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseas...

DiaMedica Therapeutics Inc. (DMAC) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants Rick Pauls - President & Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig...

DiaMedica Therapeutics (DMAC): Q1 GAAP EPS of -$0.19.Cash, cash equivalents and marketable securities of $23.4MPress Release For further details see: DiaMedica Therapeutics reports Q1 results

Investigational New Drug (IND) Application Submitted for Phase 2/3 AIS Study Plan to Initiate Phase 2/3 AIS Trial in Summer 2021 REDUX Phase 2 Diabetic Kidney Disease Cohort Readout Expected in Q2 2021 Cash Runway Through Mid-2022 ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesd...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Rick Pauls, President and CEO, will deliver a corporate presentation at B. Riley’...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the National Kidney Foundation (NKF) 2021 Sp...

DiaMedica Therapeutics Inc. (DMAC) Q4 2020 Results Earnings Conference Call March 11, 2021, 08:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Etzer Darout - Guggenhei...

DiaMedica Therapeutics (DMAC): FY GAAP EPS of -$0.78 misses by $0.06.The Company had cash, cash equivalents and marketable securities of $27.5 million, current liabilities of $2.0 million and working capital of $25.9 million as of December 31, 2020.Press Release For further details see: ...

Productive Type B Pre-IND Meeting with FDA Provides Clarity for Planned Stroke Study Program On Track to Initiate Phase 2/3 AIS Trial in Summer 2021 REDUX Phase 2 Diabetic Kidney Disease Cohort Readout Expected in Q2 2021 ReMEDy Phase 2 AIS Stud...